Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14812851 | 0.93 | KCNK3 (0.50) | KCNK3KMT2AMAPTMEN1KDM4E | |
| SCHEMBL18932675 | 0.92 | KCNK3 (0.48) | KCNK3KMT2AMAPTMEN1KDM4E | |
| SCHEMBL14811913 | 0.92 | KCNK3 (0.48) | KCNK3KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL14813035 | 0.92 | KCNK3 (0.48) | KCNK3KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL14812701 | 0.92 | KCNK3 (0.48) | KCNK3KMT2AMAPTMEN1KDM4E | |
| SCHEMBL14813041 | 0.88 | KCNK3 (0.45) | KCNK3KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL14812728 | 0.87 | KCNK3 (0.43) | KCNK3KMT2AMAPTMEN1KDM4E | |
| SCHEMBL18932931 | 0.85 | CA12 (0.43) | KCNK3KMT2AMAPTMEN1KDM4E | |
| SCHEMBL14811446 | 0.84 | KCNK3 (0.44) | KCNK3KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL8487213 | 0.84 | MEN1 (0.49) | KCNK3KMT2AMAPTMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155259-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2018-12-18 | — | — | US | disclosed |
| EP-2763986-B1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (NL) | 2017-06-07 | — | — | EP | disclosed |
| EP-2763986-B1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (NL) | 2017-06-07 | — | — | EP | disclosed |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-9127007-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-09-08 | — | — | US | disclosed |
| US-9127007-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-09-08 | — | — | US | disclosed |
| US-9127007-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-09-08 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| EP-2763986-A1 | FSH RECEPTOR ANTAGONISTS | Merck Sharp & Dohme B.V. (NL) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013041458-A1 | FSH RECEPTOR ANTAGONISTS | MSD OSS B.V. (NL) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013041458-A1 | FSH RECEPTOR ANTAGONISTS | MSD OSS B.V. (NL) | 2013-03-28 | — | — | WO | disclosed |
| US-5965575-A | N-aryl piperidine compounds as 5HT1B antagonists | ADIR ET COMPAGNIE (FR) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | FSHR, GNRHR, LHCGR | KCNK3 902/4885KMT2A 931/4885MAPT 4483/4885 |
| US-10155259-B2 | FSH receptor antagonists | FSHR, GNRHR, LHCGR | KCNK3 1027/4885KMT2A 920/4885MAPT 4640/4885 |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | FSHR, GNRHR, LHCGR | KCNK3 1027/4885KMT2A 920/4885MAPT 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.